Merck KGaA operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Merck KGaA with three other
pharmaceutical manufacturers in Europe:
of the United Kingdom
sales of £16.60 billion [US$21.65 billion]
of which 100%
Novo Nordisk As
(111.83 billion Danish Kroner [US$16.92 billion]
of which 84%
was Diabetes and obesity), and
Lonza Group AG
based in Switzerland
(5.54 billion Swiss Francs [US$5.48 billion]
of which 56%
Merck KGaA reported sales of 14.84 billion Euro (US$16.76 billion)
December of 2018.
decrease of 3.2%
versus 2017, when the company's sales were 15.33 billion Euro.
Contributing to the drop in overall sales was the 10.8% decline
in Healthcare, from 7.00 billion Euro to 6.25 billion Euro.
There were also decreases in sales in
Performance Materials (down 1.6% to 2.41 billion Euro)
However, these declines were partially offset by the increase in sales of
Life Science (up 5.2% to 6.19 billion Euro)